Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab + Chemotherapy in NSCLC with Brain Metastases
NCT05012254Phase 2Active, not recruiting
- Sponsor
- Fundación GECP
- Start
- Nov 2021
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in non-small cell lung cancer (NSCLC), brain metastases, sponsored by Fundación GECP. Started Nov 2021; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT05012254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05012254.